Conquering Diseases

Study Of 6 Vs. 12 Months Of Her2 Medicine After Breast Cancer Surgery

Description

Seeking adults with HER2-positive breast cancer who finished chemotherapy plus trastuzumab and breast surgery, and had no cancer found at surgery. This study compares 6 months to 12 months of HER2 medicine to keep cancer from coming back.

Overview

We are studying how long people with HER2-positive breast cancer need to take HER2 medicine after surgery. Everyone gets trastuzumab, with or without pertuzumab. A computer picks whether you take it for about 6 months or about 12 months. Your doctor will then check on you for 10 years.

What we're hoping for

We are studying if 6 months of HER2 medicine works as well as 12 months to keep cancer from coming back for people who have completed chemotherapy plus trastuzumab and breast surgery for HER2-positive breast cancer.

Additional Information

ClinicalTrials.gov Identifier: NCT06876714

 Principal Investigator

Ryann  Quinn, MD

UMass Chan Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989